MCF7aro Let-R Cell Line

Cat. #151781

MCF7aro Let-R Cell Line

Cat. #: 151781

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-5 days

Organism: Human

Tissue: Breast

Disease: Cancer

Model: Tumour line


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Marie McIlroy

Institute: Royal College of Surgeons Ireland (RCSI)

Tool Details
Target Details

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: MCF7aro Let-R Cell Line
  • Cancer: Breast cancer
  • Cancers detailed: Breast cancer
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: MCF7
  • Organism: Human
  • Tissue: Breast
  • Disease: Cancer
  • Model: Tumour line
  • Conditional: Yes
  • Description: MCF7aro Let-R Cell Line is a human cell line model of aromatase inhibitor resistant breast cancer.
  • Production details: Letrozole (aromatase inhibitor) sensitive cells (MCF-7aro) were developed by stable transfection of the aromatase gene (CYP19); Letrozole-resistant cells (MCF-7aro Let-R) were created by long-term treatment of aromatase-expressing MCF7 cells (MCF7aro) with letrozole.
  • Biosafety level: 1
  • Cellosaurus id: CVCL_W348

Target Details

  • Target: Aromatase expressing, Letrozole resistant


  • Format: Frozen
  • Growth medium: They are cultured in phenol red free Eagle's Minimum Essential Medium (Phenol-red free MEM) (Sigma Aldrich), 10% charcoal dextran stripped FCS (CDS-FCS), 1% Pen-Strep (Sigma Aldrich), 2 mM L-Glutamine (Sigma Aldrich) and 200 ?„?žg/ml G418 disulfate salt (Geneticin) (Sigma Aldrich), 2.5-8 M androstenedione and 10-6 M letrozole.
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes


  • Cellosaurus MCF-7aro Let-R (CVCL_W348)
  • O'Hara et al. 2012. Clin Cancer Res. 18(12):3305-15. PMID: 22550166.
  • AIB1:ERa transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
  • McIlroy et al. 2010. Cancer Res. 70(4):1585-94. PMID: 20145129.
  • Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].